Cargando…
lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma
Autores principales: | Yamada, Hideharu, Takahashi, Masanobu, Watanuki, Munenori, Watanabe, Mika, Hiraide, Sakura, Saijo, Ken, Komine, Keigo, Ishioka, Chikashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358600/ https://www.ncbi.nlm.nih.gov/pubmed/34457053 http://dx.doi.org/10.3892/ol.2021.12959 |
Ejemplares similares
-
lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma
por: Yamada, Hideharu, et al.
Publicado: (2021) -
Tumor suppressor miR‐193a‐3p enhances efficacy of BRAF/MEK inhibitors in BRAF‐mutated colorectal cancer
por: Hiraide, Sakura, et al.
Publicado: (2021) -
Reply to comments on “Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei”
por: Hiraide, Sakura, et al.
Publicado: (2021) -
Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei
por: Hiraide, Sakura, et al.
Publicado: (2019) -
Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer
por: Imai, Hiroo, et al.
Publicado: (2018)